Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Anushka Bakshi

- PMLiVE

Novo Nordisk shares promising phase 3 data for semaglutide in diabetes and chronic kidney disease

An estimated 40% of people living with type 1 or type 2 diabetes will develop CKD in their lifetime

- PMLiVE

AstraZeneca/Daiichi Sankyo’s Enhertu not recommended by NICE for advanced breast cancer

Breast cancer is the most common form of cancer in the UK, accounting for over 55,000 cases every year

- PMLiVE

Ipsen promotes Ioana Parsons to general manager for UK and Ireland

Parsons has most recently been serving as general manager at Ipsen Poland

- PMLiVE

AI and over-digitalisation

The possibility of errors and the need to be cautious

- PMLiVE

Evaluating the Forces Shaping Women’s Healthcare

Gaps in women’s healthcare go beyond access and cost. Do clinicians have the tools they need to understand women’s health?

Medscape Education

- PMLiVE

Sandoz receives FDA approval for first denosumab biosimilars Wyost and Jubbonti

The biosimilars have been authorised for all indications covered by Amgen's reference medicines

- PMLiVE

Merck KGaA and C4 Therapeutics enter protein degrader partnership worth $756m

The collaboration will utilise C4T’s TORPEDO platform to target and degrade disease-associated proteins

- PMLiVE

Sanofi’s Xenpozyme not recommended by NICE for ultra-rare disease ASMD

An estimated 40 to 50 people in England are living with the lysosomal storage disorder

- PMLiVE

Novartis shares positive results for spinal muscular atrophy gene therapy Zolgensma

The company said the results support the use of the one-time therapy in older and heavier children

- PMLiVE

Drugmakers submit counteroffers to US Medicare pricing negotiations

New negotiated prices are set to be announced by 1 September 2024 and implemented in 2026

- PMLiVE

Incentivising innovation in antibiotics

Why current intellectual property and regulatory data exclusivity systems are failing to stimulate innovation in the field of antibiotics and antimicrobials

- PMLiVE

Fool me once

But just once – after that, you’re on your own

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links